Thu, January 30, 2025
Wed, January 29, 2025
Tue, January 28, 2025
[ Tue, Jan 28th ]: MSN
7 Best Mutual Funds to Buy Now

Cantor Fitzgerald sees upside in select biotech stocks


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. gerald-sees-upside-in-select-biotech-stocks.html
  Print publication without navigation Published in Stocks and Investing on by MSN
          🞛 This publication is a summary or evaluation of another publication 🞛 This publication contains editorial commentary or bias from the source


  In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive outlook despite broader market uncertainties.

The article from MSN Money discusses Cantor Fitzgerald's optimistic outlook on certain biotech stocks, highlighting potential growth opportunities within the sector. The investment firm has identified several biotech companies that they believe are undervalued and poised for significant upside due to upcoming catalysts such as clinical trial results, FDA approvals, and strategic partnerships. The article mentions specific stocks like Sarepta Therapeutics, Alnylam Pharmaceuticals, and Intellia Therapeutics as having strong potential due to their innovative therapies in gene editing and rare disease treatments. Cantor Fitzgerald's analysis suggests that these companies could see substantial stock price increases if their developmental milestones are met, offering investors a chance to capitalize on the biotech sector's volatility and innovation.

Read the Full MSN Article at:
[ https://www.msn.com/en-us/money/other/cantor-fitzgerald-sees-upside-in-select-biotech-stocks/ar-AA1y4j7H ]

Publication Contributing Sources